CLINICAL_TRIALS
trial_result
· 2025-05-18
Clinical Trial Update: An Open-Label Study of Oral NNZ-2591 in Pitt Hopkins Syndrome (PTHS-001) [Phase 2]
Summary
Open-label Phase 2 study of NNZ-2591 for Pitt Hopkins Syndrome completed; results have been posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Neuren Pharmaceuticals Limited | Conditions: Pitt Hopkins Syndrome | Phase 2 | Status: COMPLETED | Results posted: 2025-05-18